Professor Nico van Zandwijk

Director and Professor of the ADRI
Medicine, Concord Clinical School
Asbestos Diseases Research Institute

C22 - Concord Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9767 9100
F: +61 2 9767 9101
E:
W: Related website
Curriculum vitae

Research interests

Professor van Zandwijk's major research interest is in thoracic oncology. He founded the department of Thoracic Oncology at the Netherlands Cancer Institute and was head of department from 1985 to 2008. His department was the first to study mediastinal staging, locoregional chemotherapy and photodynamic therapy in malignant mesothelioma. In 2007, Professor van Zandwijk was asked to become the inaugural director of the purpose built Asbestos Diseases Research Institute in Sydney. Over the years he has been involved in many clinical trials, translational research and mentoring more than 20 students who have become research leaders in the own right.

Publications

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2014

   
  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Chuan-Hao Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014), An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer. 110(2), 510-519. [Abstract]
  • Cheng, N., van Zandwijk, N., Reid, G. (2014), Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5. PloS One. 9(3), e90374. [Abstract]

2013

   
  • Wright, C., Kirschner, M., van Zandwijk, N., Reid, G. (2013), Does miR-1 play a role in malignant pleural mesothelioma development and progression?. Chest. , 1971. [Abstract]
  • van Zandwijk, N. (2013), Clinical practice guidelines for malignant pleural mesothelioma. Journal of Thoracic Disease. 5, 724-725. [Abstract]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013), Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology. 9(3), 273-279. [Abstract]
  • Reid, G., Pel, M., Kirschner, M., Cheng, Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., McCaughan, B., Klebe, S., Brahmbhatt, H., Macdiarmid, J., van Zandwijk, N. (2013), Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology. 24(12), 3128-3135. [Abstract]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013), Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer. 14(2), 164-171. [Abstract]
  • Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013), ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 8(10), 1317-1328. [Abstract]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013), Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer. 21(3), 697-705. [Abstract]
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013), Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Internal Medicine Journal. 43(4), 402-410. [Abstract]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013), Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data From Patients Seeking Compensation From the New South Wales Dust Diseases Board. Clinical Lung Cancer. 14(1), 70-77. [Abstract]
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013), Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer. 21(7), 1879-1884. [Abstract]
  • Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013), The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics. 4, 94. [Abstract]
  • Wright, C., Kirschner, M., Cheng, Y., O'Byrne, K., Gray, S., Schelch, K., Hoda, M., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2013), Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PloS One. 8(8), e70940. [Abstract]
  • Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013), Malignant pleural mesothelioma. Cancer Forum. 37(2), 181-185.
  • Kirschner, M., van Zandwijk, N., Reid, G. (2013), Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics. 4, 56. [Abstract]

2012

   
  • Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., Klebe, S., Mutsaers, S., van Zandwijk, N., Reid, G. (2012), Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 7(7), 1184-1191. [Abstract]
  • Linton, A., Vardy, J., Clarke, S., van Zandwijk, N. (2012), The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology/Hematology. 84(2), 200-212. [Abstract]
  • Manegold, C., van Zandwijk, N., Szczesna, A., Zatloukal, P., Au, J., Blasinska-Morawiec, M., Serwatowski, P., Krzakowski, M., Jassem, J., Tan, E., Benner, R., Ingrosso, A., Meech, S., Readett, D., Thatcher, N. (2012), A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1), 72-77. [Abstract]

2011

   
  • Heigener, D., Wu, Y., van Zandwijk, N., Mali, P., Horwood, K., Reck, M. (2011), Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer. 74(2), 274-279. [Abstract]
  • Weder, W., Stahel, R., Baas, P., Dafni, U., de Perrot, M., McCaughan, B., Nakano, T., Pass, H., Robinson, B., Rusch, V., Sugarbaker, D., van Zandwijk, N. (2011), The MARS feasibility trial: conclusions not supported by data. Lancet Oncology. 12(12), 1093-1094. [Abstract]
  • Reid, G., Kirschner, M., van Zandwijk, N. (2011), Circulating microRNAs: Association with disease and potential use as biomarkers. Critical reviews in oncology/hematology. 80(2), 193-208. [Abstract]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011), Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology. 6(11), 1923-1929. [Abstract]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., Klebe, S. (2011), Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 43(4), 313-7. [Abstract]
  • Kao, S., Reid, G., van Zandwijk, N., Henderson, D., Klebe, S. (2011), Molecular biomarkers in malignant mesothelioma: state of the art. Pathology. 43(3), 201-112. [Abstract]
  • Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011), Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 6(3), 602-605. [Abstract]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., Klebe, S. (2011), Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 43(2), 128-132. [Abstract]
  • Schaake, E., Aukema, T., Belderbos, J., Uyterlinde, W., van Zandwijk, N., Valdes Olmos, R., Verheij, M., Vincent, A., van den Heuvel, M. (2011), Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study. European Journal of Clinical and Medical Oncology. 3(3), 65-71.
  • Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011), Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PloS One. 6(9), e24145. [Abstract]

2010

   
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010), High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research. 16(23), 5805-5813. [Abstract]
  • Kao, S., Reid, G., Lee, K., Vardy, J., Clarke, S., van Zandwijk, N. (2010), Malignant Mesothelioma. Internal Medicine Journal. 40(11), 742-750. [Abstract]
  • Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., Krzakowski, M., Heigener, D. (2010), Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology. 5(10), 1616-1622. [Abstract]
  • Kappers, I., van Sandick, J., Burgers, S., Belderbos, J., van Zandwijk, N., Klomp, H. (2010), Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. Lung Cancer. 68(2), 222-227. [Abstract]

2009

   
  • Kappers, I., van Sandick, J., Burgers, J., Belderbos, J., Wouters, M., van Zandwijk, N., Klomp, H. (2009), Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. European Journal of Cardio-Thoracic Surgery. 36(4), 741-746. [Abstract]
  • Smit, E., Burgers, S., Biesma, B., Smit, H., Eppinga, P., Dingemans, A., Joerger, M., Schellens, J., Vincent, A., van Zandwijk, N., Groen, H. (2009), Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology. 27(12), 2038-2045. [Abstract]
  • Van den Heuvel, M., Burgers, S., van Zandwijk, N. (2009), Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clinical Lung Cancer. 10(2), 99-105. [Abstract]
  • Geurts, T., Balm, A., van Velthuysen, M., van Tinteren, H., Burgers, J., van Zandwijk, N., Klomp, H. (2009), Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head & neck. 31(2), 220-226. [Abstract]
  • Geurts, T., van Velthuysen, M., Broekman, F., van Huysduynen, T., van den Brekel, M., van Zandwijk, N., van Tinteren, H., Nederlof, P., Balm, A., Brakenhoff, R. (2009), Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clinical cancer research. 15(3), 980-985. [Abstract]
  • Roepman, P., Jassem, J., Smit, E., Muley, T., Niklinski, J., van de Velde, T., Witteveen, A., Rzyman, W., Floore, A., Burgers, S., Giaccone, G., Meister, M., Dienemann, H., Skrzypski, M., Kozlowski, M., Mooi, W., van Zandwijk, N. (2009), An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clinical cancer research. 15(1), 284-290. [Abstract]
  • van Zandwijk, N. (2009), Lung cancer: oncogenesis and prevention. In: Thoracic Malignancies. (pp.1-14).United Kingdom: European Respiratory Society.
  • van Zandwijk, N. (2009), Individualization of treatment in non-small cell lung cancer. F1000 Medicine Reports. 1, 24. [Abstract]

2008

   
  • Kappers, I., Klomp, H., Burgers, J., Van Zandwijk, N., Haas, R., van Pel, R. (2008), Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. Journal of clinical oncology. 26(25), 4205-4207. [Abstract]
  • van den Berg, R., Teertstra, H., van Zandwijk, N., van Tinteren, H., Visser, C., Pasic, A., Sutedja, T., Baas, P., Golding, R., Postmus, P., Smit, E. (2008), CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung cancer. 60(1), 57-61. [Abstract]
  • Kappers, I., Belderbos, J., Burgers, J., van Zandwijk, N., Groen, H., Klomp, H. (2008), Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. Lung cancer. 59(3), 385-390. [Abstract]
  • Gallegos Ruiz, M., Floor, K., Roepman, P., Rodriguez, J., Meijer, G., Mooi, W., Jassem, E., Niklinski, J., Muley, T., van Zandwijk, N., Smit, E., Beebe, K., Neckers, L., Ylstra, B., Giaccone, G. (2008), Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE. 3(3), e0001722. [Abstract]